Skip to main content


Fig. 3 | BMC Medicine

Fig. 3

From: Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study

Fig. 3

Benefits from extension to low-risk 2–16-year-old children. Benefits (in terms of non-death and death-associated Quality-Adjusted Life Days per year and per person of that age and risk group) gained from extension of vaccination to low-risk 2–16-year-old children. The benefit is given for each age and risk group (pink bars low risk, blue bars high risk). Note the change of scale in the last panel

Back to article page